Trust is one of the great intangibles in the agency–client relationship. It probably affects the choice of an agency in the first place. With trust comes loyalty, and with loyalty comes a willingness to take the kinds of risks that lead to truly breakthrough ideas, without fear of penalty and failure.
Trust is one of the great intangibles in the agency–client relationship. It probably affects the choice of an agency in the first place. With trust comes loyalty, and with loyalty comes a willingness to take the kinds of risks that lead to truly breakthrough ideas, without fear of penalty and failure.
Communication is another secret to maximizing agency value. And I define maximizing agency value as consistently innovating differentiating ideas that drive products and markets. The more a client takes the time to communicate about not only the brand and the market, but also about the company culture, processes, people, expectations, likes, dislikes, business philosophy, past success, past failure, etc., the more an agency can deliver on expectations.
Clients and their Agencies must be flexible with one another. Especially since they often work through the tedium of tight timelines and tight budgets. Appreciation also informs the best team relationships. There is no substitute for members generously sharing their observations of a job well done, a great idea, an ingenious innovation, or a can-do attitude.
Listening to another point of view, really hearing it, is pivotal to building team and producing great work. When one person (or side) of a relationship comes to the table with a fixed and unmovable viewpoint, a disservice is done to the creative process. Spirited debate is the fuel that drives great thinking, and open minds are wide windows to new and differentiating ideas.
Flashpoint, a full-service healthcare communications agency, is three years old and has roped in such megabrands as Herceptin, Avastin (managed care), and the Cypher drugeluting stent.
Telephone: 212-894-9750
E-mail: info@flashpointmedica.com
Web site: flashpointmedica.com
The Weight-Loss Gold Rush: Legal and Regulatory Implications
July 11th 2024Jim Shehan, chair of the FDA Regulatory practice, Lowenstein Sandler, discusses how the FDA and other regulators likely to respond to the increased public interest and potential off-label use of GLP-1 drugs, what needs to be done for GLP-1s to be covered, advice for investors and financiers considering entering the weight-loss medication market and more.
Healthcare Marketing Strategies for Reaching Diverse Audiences
May 14th 2024Amanda Powers-Han, Chief Marketing Officer, Greater Than One, and Pharmaceutical Executive Editorial Advisory Board member, discusses how improved DE&I in healthcare marketing strategies can not only reach diverse audiences more effectively but also contribute to improved patient care outcomes, challenges faced in crafting culturally sensitive messages, and much more.